| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 01/02/2002 | EP1165805A1 Dsp-2 dual-specificity map kinase phosphatase |
| 01/02/2002 | EP1165795A2 Streptococcus pneumoniae antigens |
| 01/02/2002 | EP1165785A1 48 human secreted proteins |
| 01/02/2002 | EP1165784A2 Nucleic acids including open reading frames encoding polypeptides; "orfx" |
| 01/02/2002 | EP1165778A2 Casb618 polynucleotides and polypeptides and their use |
| 01/02/2002 | EP1165777A2 Genes encoding human potassium channel proteins |
| 01/02/2002 | EP1165774A2 Casb619 involved in colon cancers |
| 01/02/2002 | EP1165773A1 Advanced antigen presentation platform |
| 01/02/2002 | EP1165770A2 Methods for the identification and validation of functional intracellular targets with intramers or in vivo selection |
| 01/02/2002 | EP1165758A2 Regulation of the expression of transcriptional repressor genes using nucleic acid molecules |
| 01/02/2002 | EP1165754A1 Pharmaceutical compositions comprising circulating blood cells, preferably monocytes and uses thereof |
| 01/02/2002 | EP1165606A1 50 human secreted proteins |
| 01/02/2002 | EP1165604A2 Proteins related to neuronal regeneration and uses thereof |
| 01/02/2002 | EP1165603A1 Human neurogenin 3-encoding nucleotide sequences |
| 01/02/2002 | EP1165602A1 49 human secreted proteins |
| 01/02/2002 | EP1165594A1 Antisense oligonucleotide modulation of stat3 expression |
| 01/02/2002 | EP1165591A1 47 human secreted proteins |
| 01/02/2002 | EP1165590A1 49 human secreted proteins |
| 01/02/2002 | EP1165587A1 50 human secreted proteins |
| 01/02/2002 | EP1165586A1 TCL-1b GENE AND PROTEIN AND RELATED METHODS AND COMPOSITIONS |
| 01/02/2002 | EP1165493A1 Nitrogen mustard compounds and prodrugs therefor |
| 01/02/2002 | EP1165185A2 Human tumor necrosis factor receptor-like 2 |
| 01/02/2002 | EP1165145A1 Antisense modulation of mdmx expression |
| 01/02/2002 | EP1165143A2 Method for expressing proteins |
| 01/02/2002 | EP1165140A2 Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
| 01/02/2002 | EP1165135A1 Method of affecting cholesterol catabolism using nucear bile acid receptor |
| 01/02/2002 | EP1165134A1 Use of anti-ferritin monoclonal antibodies in the treatment of some cancers |
| 01/02/2002 | EP1165132A2 Dry formulation for transcutaneous immunization |
| 01/02/2002 | EP1165124A1 Recombinant neospora antigens and their uses |
| 01/02/2002 | EP1165114A1 Use of a lectin or conjugates for modulation of c-fibre activity |
| 01/02/2002 | EP1165113A2 USE OF ErbB RECEPTOR LIGANDS IN TREATING DIABETES |
| 01/02/2002 | EP1165110A2 Antagonists of hmg1 for treating inflammatory conditions |
| 01/02/2002 | EP1165100A2 Methods of treating schizophrenia |
| 01/02/2002 | EP1165047A1 Fusogenic lipids and vesicles |
| 01/02/2002 | EP0934342B1 Composition containing chitosan |
| 01/02/2002 | EP0877796A4 Compositions and methods for mediating cell cycle progression |
| 01/02/2002 | EP0877549A4 Methods and compositions for the reduction of xenotransplantation rejection |
| 01/02/2002 | EP0822829B1 Use of glial neurotrophic factor (gdnf) for treatment of hearing disorders |
| 01/02/2002 | CN1329669A Streptococcal C5a peptidase vaccine |
| 01/02/2002 | CN1329509A Adeno-associated vectors for expression of factor VIII target cells |
| 01/02/2002 | CN1329167A A novel polypeptide-human non-integral protein-metalloprotease 10.67 and polynucleotide for coding this polypeptide |
| 01/02/2002 | CN1329092A A novel polypeptide-human RS3 protien 18 and polynucleotide for coding this polypeptide |
| 01/02/2002 | CN1329072A A novel polypeptide-human G protein subunit 12.65 and polynucletide for coding this polypeptide |
| 01/02/2002 | CN1329018A A novel polypeptide-phytochrome 9.9 and polynucleotide for coding this polypeptide |
| 01/01/2002 | US6335436 Antisense oligonucleotide coupled to ligand such as d-cycloserine, d-glucosamine, or biotin which binds to receptor on mycobacterium; hybridizes to aspartokinase or aspartate semialdehyde dehydrogenase genes |
| 01/01/2002 | US6335433 nrdD |
| 01/01/2002 | US6335424 ribG |
| 01/01/2002 | US6335199 Gene therapy |
| 01/01/2002 | US6335195 Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation |
| 01/01/2002 | US6335194 Antisense modulation of survivin expression |
| 01/01/2002 | US6335185 Bacteriophage vectors generated by bacteriophage/plasmid recombination |
| 01/01/2002 | US6335160 Methods and compositions for polypeptide engineering |
| 01/01/2002 | US6335156 Screening for anticarcinogenic/antitumor agents; incubate cells with antitumor agent, monitor cells for expression of reporter molecules |
| 01/01/2002 | US6335016 Chicken embryo lethal orphan (CELO) virus |
| 01/01/2002 | US6335011 Methods for delivering DNA to muscle cells using recombinant adeno-associated virus virions to treat lysosomal storage disease |
| 01/01/2002 | US6335009 Enhancing sensitivity of cancer tumor cell to dna damaging agent or irradiation by delivering promoter linked to a poly (adp-ribose)-polymerase encoding polynucleotide |
| 12/29/2001 | CA2351904A1 Target |
| 12/27/2001 | WO2001098775A1 Regulation of the p21 gene and uses thereof |
| 12/27/2001 | WO2001098536A2 METHOD FOR ACTIVATING PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-$g(g) |
| 12/27/2001 | WO2001098522A2 Positively-charged peptide nucleic acid analogs with improved properties |
| 12/27/2001 | WO2001098515A2 Gene-regulating conjugates |
| 12/27/2001 | WO2001098512A2 Control of metabolism with compositions of the human 2-oxoglutarate carrier |
| 12/27/2001 | WO2001098511A1 Tumour-cell specific gene expression and its use in cancer therapy |
| 12/27/2001 | WO2001098506A2 Methods and means for regulation of gene expression |
| 12/27/2001 | WO2001098500A1 Receptor binding molecules |
| 12/27/2001 | WO2001098487A1 Polynucleotides and polypeptides linked to blood pressure regulation and/or fatigue |
| 12/27/2001 | WO2001098486A1 Mutation associated with epilepsy |
| 12/27/2001 | WO2001098482A2 Liver-specific gene expression cassettes, and methods of use |
| 12/27/2001 | WO2001098481A2 Renal regulatory elements and methods of use thereof |
| 12/27/2001 | WO2001098478A2 Clk-2, cex-7 and coq-4 genes, and uses thereof |
| 12/27/2001 | WO2001098476A1 Polynucleotides encoding human serine proteases |
| 12/27/2001 | WO2001098361A2 Agonist anti-trk-c monoclonal antibodies |
| 12/27/2001 | WO2001098360A2 Gp354 nucleic acids and polypeptides |
| 12/27/2001 | WO2001098355A2 Cgi-69 compositions and methods of use |
| 12/27/2001 | WO2001098351A2 G-protein coupled receptors |
| 12/27/2001 | WO2001098350A2 Compositions comprising net-4 modulations and their use for treating neoplastic disease |
| 12/27/2001 | WO2001098344A2 Angiogenesis-modulating compositions and uses |
| 12/27/2001 | WO2001098343A2 Conserved diaphanous-related formin autoregulatory domain (dad) |
| 12/27/2001 | WO2001098333A2 Modification of hepatitis b core antigen |
| 12/27/2001 | WO2001098321A1 Inhibition of human squamous cell carcinoma in vivo by egfr antisense rna |
| 12/27/2001 | WO2001097872A1 Bioadhesive compositions and methods of preparation and use |
| 12/27/2001 | WO2001097857A1 Preparations for oligonucleotide transfer |
| 12/27/2001 | WO2001097843A2 Methods for enhancing antibody-induced cell lysis and treating cancer |
| 12/27/2001 | WO2001097828A2 Rhob as a suppressor of cancer cell growth and cell transformation |
| 12/27/2001 | WO2001078894A9 Novel human gene relating to respiratory diseases, obesity, and inflammatory bowel disease |
| 12/27/2001 | WO2001070254A9 Use of human not1 and not1a orphan receptors |
| 12/27/2001 | WO2001059088A3 Vector |
| 12/27/2001 | WO2001055310A3 Nucleic acids, proteins, and antibodies |
| 12/27/2001 | WO2001053505A3 Herpes virus strains for gene therapy |
| 12/27/2001 | WO2001049711A3 Nucleic acids encoding (poly)peptides having chips activity |
| 12/27/2001 | WO2001045672A3 Mixed structures resulting from the incorporation of a biological macromolecule in a liquid crystal phase of amphiphiles |
| 12/27/2001 | WO2001043760A3 Use of ucp3 polynucleotides and polypeptides |
| 12/27/2001 | WO2001032711A3 Adeno-associated virus aav rep78 major regulatory protein, mutants thereof and uses thereof |
| 12/27/2001 | WO2001031019A3 Neisserial antigenic peptides |
| 12/27/2001 | WO2000064864A9 N-protected amines and their use as prodrugs |
| 12/27/2001 | US20010056077 Pharmaceutical composition for treatment of duchenne muscular dystrophy |
| 12/27/2001 | US20010056076 Treatment of acute lung injury and fibrosis with antagonists of alphavbeta6 |
| 12/27/2001 | US20010056073 Revascularizing ischemic tissue or improving vascular flow of ischemic tissue by administering angiogenesis inducing gene encoding angiogenesis growth factor encapsulated in liposomal carrier vehicle into ischemic tissue |
| 12/27/2001 | US20010055596 Compositions and methods for therapy and diagnosis of colon cancer |
| 12/27/2001 | US20010055590 Method for enhancing myoblast migration and invasion in the context of gene therapy |